TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

• Published in: Journal of microbiology, immunology and infection Vol. 53; no. 3; pp. 368 - 370
• Main Authors: Wu, Dandan, Yang, Xuexian O.
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 01.06.2020; Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC; Elsevier
• Subjects: Betacoronavirus - immunology; Coronavirus Infections - drug therapy; Coronavirus Infections - pathology; COVID-19; Cytokine Release Syndrome - drug therapy; Cytokine storm; Cytokines - biosynthesis; Cytokines - immunology; Humans; JAK2 inhibitor; Janus Kinase 2 - antagonists & inhibitors; Pandemics; Pneumonia, Viral - drug therapy; Pneumonia, Viral - pathology; Pyrrolidines - pharmacology; SARS-CoV-2; Sulfonamides - pharmacology; TH17; Th17 Cells - immunology; COVID-19; SARS-CoV-2; JAK2 inhibitor; Cytokine storm; TH17

COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune prof...